Ligand Pharma (LGND) Tops Q2 EPS by 60c
Tweet
Share
E-mailGet Alerts LGND Hot Sheet
Price: $287.59 --0%
Financial Fact:
Total operating costs and expenses: 16.15M
Today's EPS Names:
ZTO, AMMX, AFIB, More
Financial Fact:
Total operating costs and expenses: 16.15M
Today's EPS Names:
ZTO, AMMX, AFIB, More
Join SI Premium – FREE
Ligand Pharma (NASDAQ: LGND) reported Q2 EPS of $1.03, $0.60 better than the analyst estimate of $0.43. Revenue for the quarter came in at $57.4 million versus the consensus estimate of $37.73 million.
For earnings history and earnings-related data on Ligand Pharma (LGND) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Opera Limited (OPRA) Misses Q2 EPS by 1c ; Offers Guidance
- Iridex Corp (IRIX) Misses Q2 EPS by 5c
- Target (TGT) Tops Q2 EPS by $1.78, Beats on Revenue; Offers FY27 EPS Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
